Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Source filing unavailable
Q2 2012 · —
Revenue$1.83B$1.83B−7.4% vs Q2 2011 Net Income-$3.58B-$3.58BN/M vs Q2 2011 EPS Diluted-$2.51-$2.51N/M vs Q2 2011 Gross Profit$1,250,000,000−2.9% Operating Income-$3,587,000,000N/M Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
$407,000,000
+4.4%
Free Cash Flowderived$355,000,000+15.6% Margins · derivedGross margin68.4%+3.2 pt vs Q2 2011
Operating margin-196.2%−208.2 pt vs Q2 2011
Net margin-195.7%−203.1 pt vs Q2 2011